tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
GILD is currently covered by 25 analysts with an average price target of $122.58. This is a potential upside of $20.08 (19.59%) from yesterday's end of day stock price of $102.5.
Gilead Sciences's activity chart (see below) currently has 612 price targets and 589 ratings on display. The stock rating distribution of GILD is 46.67% BUY and 53.33% HOLD.
Analysts average stock forecasts to be materialized ratio is 76.26% with an average time for these price targets to be met of 963.54 days.
Highest price target for GILD is $140, Lowest price target is $83, average price target is $102.86.
Most recent stock forecast was given by MATTHEW HARRISON from MORGAN STANLEY on 25-Apr-2025.
1/28/13 2 for 1
6/25/07 2 for 1
9/7/04 2 for 1
3/8/02 2 for 1
2/22/01 2 for 1
Gilead Sciences is a bio pharmaceutical company that specializes in discovering, developing, and commercializing innovative medicines for the treatment of unmet medical needs. Founded in 1987 and headquartered in Foster City, California, the company operates in the United States, Europe, and other parts of the world.
Gilead Sciences is known for its groundbreaking research and development of antiviral drugs for the treatment of HIV/AIDS. The company’s products have transformed the treatment of HIV/AIDS, allowing patients to live longer and healthier lives. Gilead Sciences has also gained recognition for its innovative therapies in oncology, hematology, and cell therapy.
Gilead Sciences focuses on addressing unmet medical needs in several therapeutic areas with a diverse portfolio of products. Here are some of the key product segments:
Gilead Sciences is a leader in developing therapies for HIV/AIDS, and the company’s HIV franchise includes several products such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. These products help to suppress the virus and slow down the progression of the disease, improving the quality of life for patients living with HIV/AIDS.
Gilead Sciences’ products for viral hepatitis include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Doctors use these products to treat chronic viral infections caused by hepatitis B and C, which can lead to serious health problems such as liver damage and cancer.
Gilead Sciences’ oncology franchise includes Yescarta, Tecartus, Trodelvy, and Zydelig. Various types of cancers, including lymphoma, leukemia, and breast cancer, are treated with these products. The company is also investing in research and development to develop new oncology therapies.
Gilead Sciences developed Letairis, an oral formulation used to treat pulmonary arterial hypertension, a type of high blood pressure that affects the arteries in the lungs.
Gilead Sciences developed AmBisome, a liposomal formulation that treats serious invasive fungal infections like aspergillosis and cryptococcosis.
They are also investing in cell therapy and gene editing technologies to develop new therapies for a wide range of diseases, including cancer, HIV/AIDS, and genetic disorders.
Currently out of the existing stock ratings of GILD, 42 are a BUY (46.67%), 48 are a HOLD (53.33%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$135
$38.09 (39.30%)
$130
22 days ago
(25-Apr-2025)
27/32 (84.38%)
$31.83 (30.85%)
600
Buy
$130
$33.09 (34.15%)
$115
1 months 20 days ago
(27-Mar-2025)
3/4 (75%)
$18.84 (16.95%)
86
Buy
$126
$29.09 (30.02%)
$109
2 months 12 days ago
(04-Mar-2025)
2/3 (66.67%)
$11.26 (9.81%)
45
Buy
$140
$43.09 (44.46%)
$120
2 months 12 days ago
(04-Mar-2025)
16/18 (88.89%)
$25.26 (22.01%)
486
Hold
$90
$-6.91 (-7.13%)
$84
3 months 5 days ago
(11-Feb-2025)
65/74 (87.84%)
$-13.31 (-12.88%)
1649
What is GILD (Gilead Sciences) average time for price targets to be met?
Which analyst has the current highest performing score on GILD (Gilead Sciences) with a proven track record?
Which analyst has the most public recommendations on GILD (Gilead Sciences)?
Which analyst is the currently most bullish on GILD (Gilead Sciences)?
Which analyst is the currently most reserved on GILD (Gilead Sciences)?
